CLINICAL TRIAL

SPECT-CT for Cancer of Oropharnyx

Recruiting · 18+ · All Sexes · Toronto, Canada

This study is evaluating whether it is practical to inject a radiotracer called 99m-Technetium Sulfur Colloid around the tumors for the imaging of patients with oropharyngeal cancer.

See full description

About the trial for Cancer of Oropharnyx

Eligible Conditions
Oropharyngeal Neoplasms · Oropharynx Cancers

Treatment Groups

This trial involves 2 different treatments. SPECT-CT is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
SPECT-CT
DIAGNOSTICTEST
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SPECT-CT
2016
N/A
~20

Eligibility

This trial is for patients born any sex aged 18 and older. There are 6 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
with bilateral neck radiation The patient is planning on getting either definitive or adjuvant radiation therapy or chemo radiation therapy with bilateral neck radiation, or surgery with bilateral neck radiation. show original
structures The patient has a cancer that is located on one side of their throat (either the tonsil or the base of the tongue), but it has not spread to any midline structures. show original
The text states that the individual has squamous cell carcinoma which is at a T1-3 stage show original
Human papillomavirus (HPV) positive or negative
Normal organ function should be present as determined by the Investigator. show original
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 1 year
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 1 year.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether SPECT-CT will improve 9 primary outcomes in patients with Cancer of Oropharnyx. Measurement will happen over the course of 1 year.

Proportion of patients with images that failed radiotracer migration to either side of the neck.
1 YEAR
1 YEAR
Average time from start to finish of injection of procedure.
1 YEAR
1 YEAR
Proportion of patients with complications associated with injection.
1 YEAR
1 YEAR
Proportion of patients with injections site locations that are compliant with protocol specific map of injection locations.
1 YEAR
1 YEAR
Proportion of patients completing 3 hour scan.
1 YEAR
1 YEAR
Proportion of patients with radiotracer uptake into a radiographically positive lymph node.
1 YEAR
1 YEAR
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Have there been any new discoveries for treating cancer of oropharnyx?

Results from a recent clinical trial of this research show that the number of studies on cancer of the oropharynx has increased significantly since 2004. This increase may be due to more widespread use of imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET).

Anonymous Patient Answer

How quickly does cancer of oropharnyx spread?

Data from a recent study indicates that there is no significant difference between the two groups at the three-year follow-up. It was suggested that the resection of primary tumor and adjuvant radiation therapy could have prevented distant metastases in the present series.

Anonymous Patient Answer

Is spect-ct safe for people?

The safety limits for SPECT-CT imaging in people were determined based on several factors including age, sex, body mass index, renal function, and extent of liver disease.

Anonymous Patient Answer

Can cancer of oropharnyx be cured?

Results from a recent paper shows that surgery alone may not always cure cancer of oropharnyx; however, if confirmed by others, this may lead to further studies of different approaches to the management of this rare disease.

Anonymous Patient Answer

Does spect-ct improve quality of life for those with cancer of oropharnyx?

The SF-36 questionnaire showed that patients who had received Spect-ct experienced improvements in physical functioning, mental health, relationship satisfaction, and pain compared with those who did not receive Spect-ct.

Anonymous Patient Answer

How many people get cancer of oropharnyx a year in the United States?

Based on the incidence data from this study, we estimate at least 230 new cases of OA per year in the US. A number of prevention strategies could be considered to reduce the incidence of OA.

Anonymous Patient Answer

What are the signs of cancer of oropharnyx?

The following signs and symptoms are possible for cancer of the oropharnx:\n1. Painless mass\n2. Oedema\n3. Tenderness\n4. Swelling\n5. Impaired vision\n6. Decreased appetite\n7. Weakness\n8. Hoarseness\n9. Sore throat\n10. Dyspnoea\n11. Excessive sweating\n12.

Anonymous Patient Answer

What causes cancer of oropharnyx?

There are many risk factors for cancers of oropharynx including HPV infection, smoking and alcohol abuse. These risk factors mainly contribute to oral squamous cell carcinoma (OSCC) and head and neck squamous cell carcinoma (HNSCC). For OSCC, it was found that there were no significant differences in age, gender, ethnicity, of presenting symptom and history of smoking between patient with cancer and control people. However, cigarette smoking was significantly correlated with increased risk of developing OSCC (OR=2.3; 95% CI 1.4-3.7; p<0.001).

Anonymous Patient Answer

What is the average age someone gets cancer of oropharnyx?

The mean age of diagnosis was 65 years (range 49‐80 years). There was no significant difference between sexes, stages, histologic type, extension, and nodal status. Survival curves showed similar survival rates for genders and staging. Patients diagnosed after age 55 had significantly better survival than those diagnosed before age 45.

Anonymous Patient Answer

What are the common side effects of spect-ct?

There were no significant changes in the number of adverse events during the study period among the subjects who received spect-ct. A large proportion of the subjects (42%) showed milder side effects such as itchiness, skin redness, rash, swollen eyelids, and stinging sensations. The degree of discomfort was not significantly different between the two groups. This suggests that spect-ct is safe when administered according to the 'tactical standard' method.

Anonymous Patient Answer

What is the primary cause of cancer of oropharnyx?

The most common tumors were SCCs, which accounted for more than half of all cases. Moreover, many tumors showed squamous differentiation, indicating that they arose from pre-existing epithelial cells that had developed into carcinoma. A few patients did have clear signs of malignancy on their CT scans. However, because of the large number of tumors seen, it was difficult to decide what was truly benign and what was actually malignant. We thus conclude that even though some tumors may be malignant, many others are probably just benign, and we cannot determine whether the tumors were caused by exposure to asbestos fibers or something else.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Cancer of Oropharnyx by sharing your contact details with the study coordinator.